Connors Investor Services’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-12,566
| Closed | -$198K | – | 162 |
|
|
2023
Q3 | $198K | Buy |
12,566
+2,500
| +25% | +$39.4K | 0.02% | 138 |
|
|
2023
Q2 | $196K | Buy |
10,066
+3,000
| +42% | +$58.4K | 0.02% | 149 |
|
|
2023
Q1 | $200K | Hold |
7,066
| – | – | 0.02% | 152 |
|
|
2022
Q4 | $207K | Buy |
+7,066
| New | +$207K | 0.03% | 143 |
|
|
2022
Q3 | – | Sell |
-6,066
| Closed | -$270K | – | 162 |
|
|
2022
Q2 | $270K | Sell |
6,066
-500
| -8% | -$22.3K | 0.03% | 124 |
|
|
2022
Q1 | $325K | Hold |
6,566
| – | – | 0.03% | 123 |
|
|
2021
Q4 | $334K | Hold |
6,566
| – | – | 0.03% | 123 |
|
|
2021
Q3 | $366K | Hold |
6,566
| – | – | 0.04% | 121 |
|
|
2021
Q2 | $281K | Buy |
+6,566
| New | +$281K | 0.03% | 131 |
|
|
2021
Q1 | – | Sell |
-3,966
| Closed | -$185K | – | 176 |
|
|
2020
Q4 | $185K | Buy |
+3,966
| New | +$185K | 0.02% | 139 |
|